News Centre
- Global
-
2022-09-30 12:58Pucotenlimab obtains approval for marketing with new achievements | Professor Guo Jun: The approval of pucotenlimab for the new indication of melanoma brings a new treatment option to immunotherapyMore -
2022-09-30 09:43Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication and brings a new treatment option for patients with melanomaMore -
2022-07-22 13:22Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing by the National Medical Products AdministrationMore -
2021-04-20 15:22Lepu Biopharma Completed Series C FinancingMore -
2021-03-05 14:49The IND application of Lepu Biopharma CG0070 Injection was accepted by CDEMore -
2020-10-26 14:43CtM Bio Co., Ltd. and the landing of scientific research cooperation project of Institute of Immunochemistry, Shanghai University of Science and TechnologyMore
